Company aligned with FDA that RUBY is a single Phase 1/2/3 trial
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates by year-end 2024
Initiated enrollment in the adolescent cohort in the RUBY trial
Entered into a license agreement providing Vertex Pharmaceuticals a non-exclusive license for Cas9
Strong financial position with operational runway expected into 2026
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.